Novartis’ groundbreaking cancer T-cell therapy CTL019 has won unanimous backing from advisers to the FDA, paving the way for approval in the coming months. There had been concerns that the ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

Novartis’ CAR-T therapy Kymriah will be available in the US to adults with relapsed large B-cell lymphoma – bringing the cell therapy into direct competition with Gilead’s rival at exactly ...

A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years. “This is ...

After injection, the CAR-T cells got to work, multiplying and seeking out the target B cells, including the pathogenic ones underlying the autoimmune conditions. This persisted for a few weeks ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

CAR T-cell expansion and persistence were superior ... Kotecha disclosed relationships with Eisai, Allogene Therapeutics, Exelixis, Novartis, Pfizer, Takeda, and Xencor. Campbell and Tannir ...

Despite the powerful cancer-fighting capabilities of treatments based on T cells containing an engineered chimeric antigen receptor (CAR) to fight a patient’s cancer, one key challenge is ...

While the use of chimeric antigen receptor (CAR) T-cell therapy has increased rapidly ... Bristol Myers Squibb, Novartis, and ...